Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study

Background Merkel cell carcinoma (MCC) is a rare, aggressive, cutaneous neuroendocrine neoplasm with annual incidence rates of 0.13–1.6 cases/100,000/year worldwide as of 2018. Chemotherapy for metastatic MCC (mMCC) has high objective response rates (ORRs), but responses are not durable and overall...
Ausführliche Beschreibung

Gespeichert in:
Autor*in:

Shailender Bhatia [verfasserIn]

Paul Nghiem [verfasserIn]

Alejandro Vanegas [verfasserIn]

Kristina Lachance [verfasserIn]

Lisa Tachiki [verfasserIn]

Kevin Chiu [verfasserIn]

Emily Boller [verfasserIn]

Murtuza Bharmal [verfasserIn]

S Phani Veeranki [verfasserIn]

Format:

E-Artikel

Sprache:

Englisch

Erschienen:

2022

Übergeordnetes Werk:

In: Journal for ImmunoTherapy of Cancer - BMJ Publishing Group, 2013, 10(2022), 8

Übergeordnetes Werk:

volume:10 ; year:2022 ; number:8

Links:

Link aufrufen
Link aufrufen
Link aufrufen
Journal toc

DOI / URN:

10.1136/jitc-2022-004904

Katalog-ID:

DOAJ024243612

Nicht das Richtige dabei?

Schreiben Sie uns!